ScholarIQanswers from OpenAlex & ORCID
Scott Berry
ResearcherPublications, citations & collaboration network
Scott Berry is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Scott Berry have?
ScholarIQindexed works
Scott Berry has 304 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Scott Berry have?
ScholarIQcitation count
Scott Berry has 19,274 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Scott Berry?
ScholarIQh-index
Scott Berry has an h-index of 62 in OpenAlex.
What is the i10-index of Scott Berry?
ScholarIQi10-index
Scott Berry has an i10-index of 143 in OpenAlex.
What is the ORCID of Scott Berry?
ScholarIQorcid
The ORCID for Scott Berry is on the source record.
What is the OpenAlex record for Scott Berry?
ScholarIQopenalex
The OpenAlex for Scott Berry is on the source record.
What are the most-cited papers on Scott Berry?
ScholarIQmost cited works
Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19
The WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Pere Domingo, Isabel Mur, Gràcia Mateo, María del Mar Gutiérrez, Virginia Pomar, Natividad Benito, Noemí Corbacho, Silvia Herrera, L F Pascual Millán, Jessica Muñoz, Jorge Malouf, Maria Ema Molas, Víctor Asensi, Juan Pablo Horcajada, Vicente Estrada, Félix Gutiérrez, Ferràn Torres, José A. Pérez‐Molina, Jesús Fortün, Luisa María Villar, Ulla Hohenthal, Harri Marttila, Tytti Vuorinen, Marika Nordberg, Mika Valtonen, Matthew J. Frigault, Michael K. Mansour, Naomi J. Patel, Ana D. Fernandes, Liam Harvey, Andrea S. Foulkes, Brian C. Healy, Ruta Shah, Ana Maria Bensaci, Ann E. Woolley, Sarah Nikiforow, Nina Lin, Manish Sagar, Harry Shrager, David S. Huckins, Matthew Axelrod, Michael Pincus, Jorge Fleisher, Jon Lampa, Piotr Nowak, Jan Vesterbacka, Johan Rasmuson, Paul Skorup, Helena Janols, Katarina Niward, Katerina Chatzidionysiou, Hilmir Ásgeirsson, Åsa Parke, Ola Blennow, Anna‐Karin Svensson, Soo Aleman, Anders Sönnerborg, Jan‐Inge Henter, AnnaCarin Horne, Farah Al-Beidh, Derek C. Angus, Djillali Annane, Yaseen M. Arabi, Abi Beane, Scott Berry, Zahra Bhimani, Marc J. M. Bonten, Charlotte Bradbury, Frank Brunkhorst, Meredith Buxton, Allen Cheng, Matt Cove, Menno D. de Jong, Lennie Derde, Lise J Estcourt, Herman Goossens, Anthony Gordon, Cameron Green, Rashan Haniffa, Nao Ichihara, François Lamontagne, Patrick R. Lawler, Edward Litton, John Marshall, Colin McArthur, Daniel F. McAuley, Shay McGuinness, Bryan J. McVerry, Stephanie Montgommery, Paul Mouncey, Srinivas Murthy, Alistair Nichol, Rachael Parke, Rachael Parke, Felipe Reyes, Kathryn Rowan, Hiroki Saito, Marlene Santos, Chris Seymour
Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer
Rita Nanda, Minetta C. Liu, Christina Yau, Rebecca Shatsky, Lajos Pusztai, Anne M. Wallace, A. Jo Chien, Andres Forero‐Torres, Erin D. Ellis, Heather Han, Amy S. Clark, Kathy S. Albain, Judy C. Boughey, Nora Jaskowiak, Anthony Elias, Claudine Isaacs, Kathleen Kemmer, Teresa Helsten, Melanie Majure, Erica Stringer-Reasor, Catherine Parker, Marie Catherine Lee, Tufia C. Haddad, Ronald Cohen, Smita Asare, Amy Wilson, Gillian L. Hirst, Ruby Singhrao, Katherine Steeg, Adam L. Asare, Jeffrey B. Matthews, Scott Berry, Ashish Sanil, Richard B. Schwab, W. Fraser Symmans, Laura van ‘t Veer, Douglas Yee, Angela DeMichele, Nola M. Hylton, Michelle Melisko, Jane Perlmutter, Hope S. Rugo, Donald A. Berry, Laura J. Esserman
The REMAP-CAP (Randomized Embedded Multifactorial Adaptive Platform for Community-acquired Pneumonia) Study. Rationale and Design
Derek C. Angus, Scott Berry, Roger Lewis, Farah Al-Beidh, Yaseen M. Arabi, Wilma van Bentum-Puijk, Zahra Bhimani, Marc J. M. Bonten, Kristine Broglio, Frank M. Brunkhorst, Allen Cheng, Jean‐Daniel Chiche, Menno D. de Jong, Michelle A. Detry, Herman Goossens, Anthony Gordon, Cameron Green, Alisa M. Higgins, Sebastiaan Hullegie, Peter Krüger, François Lamontagne, Edward Litton, John C. Marshall, Anna McGlothlin, Shay McGuinness, Paul Mouncey, Srinivas Murthy, Alistair Nichol, Genevieve O’Neill, Rachael Parke, Jane Parker, Gernot Rohde, Kathy Rowan, Anne Turner, Paul J. Young, Lennie Derde, Colin McArthur, Steven Webb
Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial
Lajos Pusztai, Christina Yau, Denise M. Wolf, Hyo S. Han, Lili Du, Anne M. Wallace, Erica String-Reasor, Judy C. Boughey, A. Jo Chien, Anthony Elias, Heather Beckwith, Rita Nanda, Kathy S. Albain, Amy S. Clark, Kathleen Kemmer, Kevin Kalinsky, Claudine Isaacs, Alexandra Thomas, Rebecca Shatsky, Theresa L. Helsten, Andres Forero‐Torres, Minetta C. Liu, Lamorna Brown Swigart, Emmanuel Petricoin, Julia Wulfkuhle, Smita Asare, Amy Wilson, Ruby Singhrao, Laura Sit, Gillian L. Hirst, Scott Berry, Ashish Sanil, Adam L. Asare, Jeffrey B. Matthews, Jane Perlmutter, Michelle Melisko, Hope S. Rugo, Richard B. Schwab, W. Fraser Symmans, Douglas Yee, Laura J. van’t Veer, Nola M. Hylton, Angela DeMichele, Donald A. Berry, Laura J. Esserman